

Asthma Indicators for LHIN 9: Central East

	Asthma Indicators for LHIN 9: Central East																						
Indicator	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017*	2018*
1. PFT used for diagnosis (% of incident asthma)†	44.08	44.42	42.89	42.09	40.50	40.19	38.40	37.25	37.09	38.03	40.02	40.61	41.27	41.57	43.09	44.83	46.18	46.30	48.82	50.28	51.91	50.83	53.78
2. PFT used for monitoring (% of prevalent asthma)†	12.59	11.27	10.78	9.76	8.93	8.45	7.26	6.49	6.23	6.18	5.98	5.88	5.85	5.74	5.73	5.59	5.53	5.24	5.14	5.43	5.62	5.77	5.73
3. ≥1 ICS prescription (% of prevalent asthma)‡	59.63	57.44	56.49	55.42	54.69	54.04	52.02	50.15	50.72	50.21	49.58	49.36	48.77	49.12	48.88	50.63	50.53	50.35	49.77	49.77	48.77	46.48	43.83
4. ≥1 β2-agonist prescription (% of prevalent asthma)‡	62.48	59.76	57.90	56.14	55.39	52.91	50.16	47.25	46.06	44.43	42.35	41.67	39.35	38.37	37.96	38.03	36.82	35.64	31.93	24.21	24.25	22.58	22.63
5. ≥1 asthma ED visit (% of prevalent asthma)	5.52	4.76	4.11	3.72	3.46	3.04	2.77	2.27	2.08	2.07	1.93	1.73	1.59	1.47	1.39	1.23	1.19	1.15	1.03	1.08	0.99	0.90	0.89
6. ≥1 asthma physician office visit (% of prevalent asthma)	37.31	33.96	30.90	29.37	27.29	26.39	23.38	21.65	21.29	20.50	19.59	18.57	17.54	16.57	16.47	14.96	14.23	13.77	13.05	12.96	12.55	12.20	12.26
7. β2-agonist use (% of prevalent asthma)‡																							
0	37.52	40.24	42.10	43.86	44.61	47.09	49.84	52.75	53.94	55.57	57.65	58.33	60.65	61.63	62.04	61.97	63.18	64.36	68.07	75.79	75.75	77.42	77.37
1-2	19.16	19.43	19.23	19.70	19.92	19.50	19.05	18.06	18.38	19.00	18.00	18.41	18.23	18.03	17.96	17.97	17.59	17.79	16.08	12.25	12.45	11.36	11.30
≥3	43.32	40.33	38.66	36.44	35.46	33.40	31.11	29.19	27.69	25.44	24.35	23.26	21.12	20.34	20.01	20.06	19.23	17.85	15.85	11.96	11.80	11.22	11.34

*Reporting period is from April 1996 to March 2019. Data for 2017 and 2018 may be incomplete due to the 2-year algorithm to identify asthma, and numbers are subject to change.

PFT = pulmonary function test; ICS = inhaled corticosteroid; ED = emergency department; ODB = Ontario Drug Benefit; OHIP = Ontario Health Insurance Plan; LHIN = Local Health Integration Network; HSU = health services use

†PFT data refers to individuals aged 7-99 years in the asthma prevalent population.

‡Drug use data refers to individuals aged 66-99 years with complete year ODB coverage in the asthma prevalent population.

Technical notes:

^aOHIP data was up to December 2019 when the tables were created.

^bFor asthma incidence from July 2017 to March 2019, PFT data for 2.5-year post asthma incidence are not complete as latest data were available up to December 2019 when the tables were created.

^cIndividuals with missing LHIN, rurality, or without OHIP coverage were excluded.

^dAsthma incidence of the year were excluded from this table, except for indicator 1.

^eIndex date is defined as the first service date of asthma HSU, or any HSU if there was no asthma HSU, or April 1 if there was no HSU during the year.

Asthma indicators - detailed description:

1. Percent of asthma incidence aged 7 years and above with a PFT in one year prior to or 2.5 years after incidence date^{a-c}
2. Percent of asthma prevalence aged 7 years and above with a PFT in one year prior to the index date^{a,c-e}
3. Percent of asthma prevalence 66 years and above with at least one prescription of ICS in one year prior to the index date^{c-e}
4. Percent of asthma prevalence aged 66 years and above with at least one prescription of β2-agonist in one year prior to the index date^{c-e}
5. Percent of asthma prevalence with at least one ED visit in one year prior to the index date^{c-e}
6. Percent of asthma prevalence with at least one physician office visit in one year prior to the index date^{c-e}
7. Distribution of the three categories of β2-agonist use for asthma prevalence aged 66 years and above^{c,d}

Source: This table uses statistics reported by the Ontario Asthma Surveillance Information System (OASIS) and data provided by ICES, Ontario.